US President Signs Federal Marijuana Reform Bill.

Dec.06.2022
US President Signs Federal Marijuana Reform Bill.
US President Joe Biden signed a federal cannabis reform bill to promote research into potential health benefits.

Last Friday, U.S. President Joe Biden officially signed an independent federal marijuana reform bill. The President signed a marijuana research bill into law, which was approved by the House of Representatives in July and authorized by the Senate last month.


The bill aims to advance research on marijuana and its potential health benefits. The law grants the U.S. Attorney General 60 days to approve specific applications or request additional information from applicants seeking to conduct research on marijuana.


The "Cannabis and Cannabinoid Research Expansion Act" is seeking to create a more efficient pathway for researchers to conduct additional studies on marijuana and its compounds.


This legislation has three components:


Firstly, to establish mechanisms for the scientific research of medical cannabis and its derivatives.


Secondly, to establish a regulatory path for commercial production of drugs containing or derived from cannabis approved by the FDA.


Thirdly, protecting doctors who discuss the risks and benefits of using marijuana and its derivatives.


According to the National Law Review, the President still opposes federal legalization of marijuana, but has advocated for some more moderate marijuana reforms, including promoting research under the Controlled Substances Act (CSA), decriminalization, and re-scheduling of marijuana.


Joe Biden has granted a large-scale pardon to Americans who were charged with federal marijuana possession offenses in October and instructed an administrative review of the marijuana scheduling. The White House recently listed these actions as one of the president's "greatest achievements.


2FIRSTS will continue to provide ongoing coverage of this issue, with updates available on the "2FIRSTSAPP". Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.